Isis, Rosetta Ink Deal to Develop miRNA-Targeting Drugs and Ambion Unveils miRNA Analysis Service | GenomeWeb

Isis, Rosetta Ink Deal to Develop miRNA-Targeting Drugs …

Isis Pharmaceuticals and Rosetta Genomics announced this week that they have established a partnership to discover and develop antisense drugs that regulate microRNAs for the treatment of hepatocellular carcinoma.

The deal brings together Rosetta's miRNA expertise and intellectual property with Isis' experience in oligonucleotide chemistry and antisense research and development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.